Suppr超能文献

中央淋巴导水管异常患者队列的遗传学病因和基因型表型相关性。

Genetics etiologies and genotype phenotype correlations in a cohort of individuals with central conducting lymphatic anomaly.

机构信息

Jill and Mark Fishman Center for Lymphatic Disorders, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.

出版信息

Eur J Hum Genet. 2022 Sep;30(9):1022-1028. doi: 10.1038/s41431-022-01123-9. Epub 2022 May 24.

Abstract

Central conducting lymphatic anomaly (CCLA) is a heterogenous disorder caused by disruption of central lymphatic flow that may result in dilation or leakage of central lymphatic channels. There is also a paucity of known genetic diagnoses associated with CCLA. We hypothesized that specific genetic syndromes would have distinct lymphatic patterns and this would allow us to more precisely define CCLA. As a first step toward "precision lymphology", we defined the genetic conditions associated with CCLA by performing a retrospective cohort study. Individuals receiving care through the Jill and Mark Fishman Center for Lymphatic Disorders at the Children's Hospital of Philadelphia between 2016 and 2019 were included if they had a lymphangiogram and clinical genetic testing performed and consented to a clinical registry. In our cohort of 115 participants, 26% received a molecular diagnosis from standard genetic evaluation. The most common genetic etiologies were germline and mosaic RASopathies, chromosomal abnormalities including Trisomy 21 and 22q11.2 deletion syndrome, and PIEZO1-related lymphatic dysplasia. Next, we analyzed the dynamic contrast magnetic resonance lymphangiograms and found that individuals with germline and mosaic RASopathies, mosaic KRASopathies, PIEZO1-related lymphatic dysplasia, and Trisomy 21 had distinct central lymphatic flow phenotypes. Our research expands the genetic conditions associated with CCLA and genotype-lymphatic phenotype correlations. Future descriptions of CCLA should include both genotype (if known) and phenotype to provide more information about disease (gene-CCLA). This should be considered for updated classifications of CCLA by the International Society of Vascular Anomalies.

摘要

中央导水管淋巴异常(CCLA)是一种由中央淋巴流中断引起的异质性疾病,可能导致中央淋巴通道扩张或渗漏。与 CCLA 相关的已知遗传诊断也很少。我们假设,特定的遗传综合征会有不同的淋巴模式,这将使我们能够更精确地定义 CCLA。作为“精准淋巴学”的第一步,我们通过进行回顾性队列研究来确定与 CCLA 相关的遗传条件。如果在费城儿童医院的 Jill 和 Mark Fishman 淋巴疾病中心接受治疗的个体接受了淋巴管造影和临床遗传检测,并同意参加临床登记,他们将被纳入研究。在我们的 115 名参与者队列中,26%的人从标准遗传评估中获得了分子诊断。最常见的遗传病因是种系和嵌合 RAS 病、染色体异常包括 21 三体和 22q11.2 缺失综合征以及 PIEZO1 相关的淋巴管发育不良。接下来,我们分析了动态对比磁共振淋巴造影,发现种系和嵌合 RAS 病、嵌合 KRAS 病、PIEZO1 相关的淋巴管发育不良和 21 三体的个体具有独特的中央淋巴流表型。我们的研究扩大了与 CCLA 相关的遗传条件以及基因型-淋巴表型相关性。未来对 CCLA 的描述应包括基因型(如果已知)和表型,以提供有关疾病的更多信息(基因-CCLA)。这应被认为是对国际血管异常学会更新的 CCLA 分类的考虑因素。

相似文献

1
Genetics etiologies and genotype phenotype correlations in a cohort of individuals with central conducting lymphatic anomaly.
Eur J Hum Genet. 2022 Sep;30(9):1022-1028. doi: 10.1038/s41431-022-01123-9. Epub 2022 May 24.
2
Central conducting lymphatic anomaly: from bench to bedside.
J Clin Invest. 2024 Apr 15;134(8):e172839. doi: 10.1172/JCI172839.
5
Complex Lymphatic Anomalies: Report on a Patient Registry Using the Latest Diagnostic Guidelines.
Lymphat Res Biol. 2023 Jun;21(3):230-243. doi: 10.1089/lrb.2022.0041. Epub 2023 Jan 27.
6
Lymphatic disorders caused by mosaic, activating KRAS variants respond to MEK inhibition.
JCI Insight. 2023 May 8;8(9):e155888. doi: 10.1172/jci.insight.155888.
7
Pathogenic variant in EPHB4 results in central conducting lymphatic anomaly.
Hum Mol Genet. 2018 Sep 15;27(18):3233-3245. doi: 10.1093/hmg/ddy218.
8
Lymphaticovenous bypass of the thoracic duct for the treatment of chylous leak in central conducting lymphatic anomalies.
J Pediatr Surg. 2019 Mar;54(3):562-568. doi: 10.1016/j.jpedsurg.2018.08.056. Epub 2018 Sep 9.
9
Case Report: gene mutation resulting in central conducting lymphatic anomaly facilitates group A sepsis.
Front Pediatr. 2024 Sep 25;12:1367532. doi: 10.3389/fped.2024.1367532. eCollection 2024.
10
Pathogenic variants in cause recessive central conducting lymphatic anomaly with lymphedema.
Sci Transl Med. 2022 Mar 2;14(634):eabm4869. doi: 10.1126/scitranslmed.abm4869.

引用本文的文献

1
Molecular targeted treatment in infants with central conducting lymphatic anomalies.
Eur J Pediatr. 2025 Aug 21;184(9):567. doi: 10.1007/s00431-025-06376-2.
2
[Lymphatic malformations in childhood and adolescence].
Radiologie (Heidelb). 2025 May;65(5):354-361. doi: 10.1007/s00117-025-01450-0. Epub 2025 Apr 22.
3
A single-cell atlas of normal and KRASG12D-malformed lymphatic vessels.
JCI Insight. 2025 Jan 28;10(5):e185181. doi: 10.1172/jci.insight.185181.
4
Molecular landscape and classification of vascular anomalies.
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):700-708. doi: 10.1182/hematology.2024000598.
5
Trametinib restores the central conducting lymphatic flow in a premature infant with Noonan syndrome.
Clin Case Rep. 2024 Jul 8;12(7):e9164. doi: 10.1002/ccr3.9164. eCollection 2024 Jul.
6
Lymphatic failure and lymphatic interventions: Knowledge gaps and future directions for a new frontier in congenital heart disease.
Semin Pediatr Surg. 2024 Jun;33(3):151426. doi: 10.1016/j.sempedsurg.2024.151426. Epub 2024 May 23.
7
Central conducting lymphatic anomaly: from bench to bedside.
J Clin Invest. 2024 Apr 15;134(8):e172839. doi: 10.1172/JCI172839.
8
Lymphatic malformations: mechanistic insights and evolving therapeutic frontiers.
J Clin Invest. 2024 Mar 15;134(6):e172844. doi: 10.1172/JCI172844.
9
Dysregulation of Lymphatic Endothelial VEGFR3 Signaling in Disease.
Cells. 2023 Dec 28;13(1):68. doi: 10.3390/cells13010068.
10
Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function.
Front Cell Dev Biol. 2023 Sep 25;11:1276333. doi: 10.3389/fcell.2023.1276333. eCollection 2023.

本文引用的文献

1
Pathogenic variants in cause recessive central conducting lymphatic anomaly with lymphedema.
Sci Transl Med. 2022 Mar 2;14(634):eabm4869. doi: 10.1126/scitranslmed.abm4869.
2
Lymphatic Malformations: Genetics, Mechanisms and Therapeutic Strategies.
Circ Res. 2021 Jun 25;129(1):136-154. doi: 10.1161/CIRCRESAHA.121.318142. Epub 2021 Jun 24.
3
How we approach the diagnosis and management of complex lymphatic anomalies.
Pediatr Blood Cancer. 2022 Aug;69 Suppl 3:e28985. doi: 10.1002/pbc.28985. Epub 2021 Apr 12.
4
Systematic Review of Magnetic Resonance Lymphangiography From a Technical Perspective.
J Magn Reson Imaging. 2021 Jun;53(6):1766-1790. doi: 10.1002/jmri.27542. Epub 2021 Feb 24.
6
A dyadic approach to the delineation of diagnostic entities in clinical genomics.
Am J Hum Genet. 2021 Jan 7;108(1):8-15. doi: 10.1016/j.ajhg.2020.11.013.
9
Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications.
Eur J Hum Genet. 2021 Jan;29(1):51-60. doi: 10.1038/s41431-020-00708-6. Epub 2020 Aug 12.
10
ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor.
Nat Med. 2019 Jul;25(7):1116-1122. doi: 10.1038/s41591-019-0479-2. Epub 2019 Jul 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验